Novo Nordisk to offer select doses of Ozempic, Wegovy at a steep discount

Until the end of March, Novo Nordisk will let people with prescriptions buy the first two doses of the drugs for $199 a month. Then the monthly cost will rise to $349.

What's Happening With Novo Nordisk Stock?

While Eli Lilly stock has surged beyond a $1 trillion market capitalization, Novo Nordisk is having difficulty keeping up, both in growth and pipeline progression.

Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies

Pharma companies are facing pricing pressure from several directions, including from the U.S. Medicare negotiations

How Novo Nordisk Is Trying to Regain Its Weight-Loss Edge

Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its Ozempic shot, originally developed to treat diabetes, could help trim their waistlines.

Denmark compensates patients for vision loss linked to Novo Nordisk drugs

By Jacob Gronholt-Pedersen COPENHAGEN (Reuters) -Four patients in Denmark, who experienced vision loss after using Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic, have been granted compensation,
Feedback